Transaction DateRecipientSharesTypePriceValue
18th September 2020Investments, Lp Rtw750,000Open or private purchase$17.00$12,750,000.00
18th September 2020Investments, Lp Rtw1,535,131Conversion of derivative$0.00
17th August 2020Investments, Lp Rtw31,450Exercise of in-the-money or at-the-money derivatives securities (usually options)$9.54$300,033.00
16th June 2020Investments, Lp Rtw3,045,000Conversion of derivative$0.00
16th June 2020Investments, Lp Rtw950,000Open or private purchase$18.00$17,100,000.00
27th May 2020Investments, Lp Rtw228,498Conversion of derivative$0.00
1st April 2020Investments, Lp Rtw26,539Open or private purchase$10.41$276,316.11
31st March 2020Investments, Lp Rtw5,000Open or private purchase$11.26$56,321.00
24th March 2020Gaurav Shah90,925Exercise of derivative$0.43$39,097.75
24th March 2020Gaurav Shah32,645Payment by withholding$13.78$449,848.10
Inotek Pharmaceuticals
Inotek Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.

Ticker: ITEK
Sector: Unknown
Industry: Unknown
SEC Central Index Key (CIK): 1281895
Exchange: None
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $163 M (0%)
Assets, Current: $255 M (-16%)
Property, Plant and Equipment, Net: $14 M (0%)
Assets: $353 M (-5%)
Liabilities, Current: $21 M (12%)
Other Liabilities, Noncurrent: $23 Th (0%)
Liabilities: $87 M (33%)
Common Stock, Value, Issued: $551 Th (0%)
Common Stock, Shares, Issued: $55 M (0%)
Retained Earnings (Accumulated Deficit): $233 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $229 Th (1045%)
Stockholders' Equity (Parent): $267 M (0%)
Liabilities and Equity: $353 M (-5%)
Research and Development: $17 M (-50%)
General and Administrative Expenses: $7 M (-51%)
Operating Income/Loss: $24 M (-50%)